HealthDay News — For patients with unresectable metastatic uveal melanoma (mUM), the drug/device combination melphalan/hepatic delivery system (HDS) is efficacious and has a favorable risk-benefit ...

Melphalan HCl 50mg/vial; pwd for IV infusion after reconstitution and dilution. Melphalan is an alkylating agent with cytotoxic action that appears to be related to the extent of its interstrand ...

Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic ...

A multi-institutional study led by Moffitt Cancer Center found that percutaneous hepatic perfusion using a melphalan hepatic ...

Melphalan 200 mg/m 2 vs melphalan 100 mg/m 2 in newly diagnosed myeloma patients: a prospective multicenter phase 3 study. Blood 115 , 1873–1879 (2010). Article CAS PubMed Google Scholar ...

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic liver cancers, annou ...

A new way to deliver cancer medicine directly to the liver may help patients with a rare and aggressive type of eye cancer ...

Salvage chemotherapy regimens including bortezomib plus steroid, alkylators plus steroid, bortezomib plus anthracycline and radiotherapy, and combined bortezomib, cyclophosphamide, melphalan and ...

The company's proprietary products, HEPZATO KIT™ (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion ...